BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marshall HT, Djamgoz MBA. Immuno-Oncology: Emerging Targets and Combination Therapies. Front Oncol. 2018;8:315. [PMID: 30191140 DOI: 10.3389/fonc.2018.00315] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 33.5] [Reference Citation Analysis]
Number Citing Articles
1 Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 2020;126:3192-201. [PMID: 32401342 DOI: 10.1002/cncr.32909] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
2 Yi M, Qin S, Zhao W, Yu S, Chu Q, Wu K. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol 2018;7:28. [PMID: 30473928 DOI: 10.1186/s40164-018-0120-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 12.8] [Reference Citation Analysis]
3 Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. Cancer Immunol Immunother 2020;69:383-97. [PMID: 31897661 DOI: 10.1007/s00262-019-02456-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Joung KI, Song JH, Suh K, Lee SM, Jun JH, Park T, Suh DC. Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. BioDrugs 2021;35:61-73. [PMID: 33331991 DOI: 10.1007/s40259-020-00459-2] [Reference Citation Analysis]
5 Williams SG, Mollaeian A, Katz JD, Gupta S. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. Expert Rev Clin Immunol 2020;16:771-85. [PMID: 32772596 DOI: 10.1080/1744666X.2020.1804362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Reithofer M, Rosskopf S, Leitner J, Battin C, Bohle B, Steinberger P, Jahn-Schmid B. 4-1BB costimulation promotes bystander activation of human CD8 T cells. Eur J Immunol 2021;51:721-33. [PMID: 33180337 DOI: 10.1002/eji.202048762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Iacobas DA. Powerful quantifiers for cancer transcriptomics. World J Clin Oncol 2020;11:679-704. [PMID: 33033692 DOI: 10.5306/wjco.v11.i9.679] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Ofori S, Awuah SG. Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. ACS Omega 2019;4:12584-97. [PMID: 31460379 DOI: 10.1021/acsomega.9b01106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
9 Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release 2021;340:1-34. [PMID: 34673122 DOI: 10.1016/j.jconrel.2021.10.006] [Reference Citation Analysis]
10 Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, Ascierto PA, McEwan P, Wagner S, Borrill J, Wu E. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer 2020;8:e000648. [PMID: 32661115 DOI: 10.1136/jitc-2020-000648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Schirrmacher V. Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines 2020;8:E61. [PMID: 32188078 DOI: 10.3390/biomedicines8030061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
12 Yang S, Lin S, Liu K, Liu Y, Xu P, Zheng Y, Deng Y, Zhang D, Zhai Z, Li N, Ren X, Dai Z, Kang H. Identification of an immune-related RNA-binding protein signature to predict survival and targeted therapy responses in liver cancer. Genomics 2021;113:795-804. [PMID: 33524497 DOI: 10.1016/j.ygeno.2021.01.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Nielsen TJ, Ring BZ, Seitz RS, Hout DR, Schweitzer BL. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon 2021;7:e06438. [PMID: 33748492 DOI: 10.1016/j.heliyon.2021.e06438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L. Breast cancer immunotherapy: Current and novel approaches. Int Immunopharmacol 2021;98:107886. [PMID: 34153663 DOI: 10.1016/j.intimp.2021.107886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 De Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, Wiedermann U, Kundi M, Zlabinger GJ, Grabmeier-Pfistershammer K, Steinberger P. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep 2019;9:11472. [PMID: 31391510 DOI: 10.1038/s41598-019-47910-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
16 Kim SW, Roh J, Lee HS, Ryu MH, Park YS, Park CS. Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. Gastric Cancer 2021;24:327-40. [PMID: 32924090 DOI: 10.1007/s10120-020-01120-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Rahman A, Jahangir C, Lynch SM, Alattar N, Aura C, Russell N, Lanigan F, Gallagher WM. Advances in tissue-based imaging: impact on oncology research and clinical practice. Expert Rev Mol Diagn 2020;20:1027-37. [PMID: 32510287 DOI: 10.1080/14737159.2020.1770599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Toner K, Bollard CM, Dave H. T-cell therapies for T-cell lymphoma. Cytotherapy 2019;21:935-42. [PMID: 31320195 DOI: 10.1016/j.jcyt.2019.04.058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Pi YN, Xia BR, Jin MZ, Jin WL, Lou G. Exosomes: Powerful weapon for cancer nano-immunoengineering. Biochem Pharmacol 2021;186:114487. [PMID: 33647264 DOI: 10.1016/j.bcp.2021.114487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kähkönen TE, Halleen JM, Bernoulli J. Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis. Cells 2021;10:1529. [PMID: 34204474 DOI: 10.3390/cells10061529] [Reference Citation Analysis]
21 Rocco D, Gregorc V, Della Gravara L, Lazzari C, Palazzolo G, Gridelli C. New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials. Expert Opin Investig Drugs 2020;29:1005-23. [PMID: 32643447 DOI: 10.1080/13543784.2020.1793956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wang Y, Zhang X, Wang Y, Zhao W, Li H, Zhang L, Li X, Zhang T, Zhang H, Huang H, Liu C. Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. Acta Pharm Sin B 2021;11:2957-72. [PMID: 34729298 DOI: 10.1016/j.apsb.2021.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
23 Congreve M, de Graaf C, Swain NA, Tate CG. Impact of GPCR Structures on Drug Discovery. Cell 2020;181:81-91. [DOI: 10.1016/j.cell.2020.03.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 30.0] [Reference Citation Analysis]
24 Pane K, Mirabelli P, Coppola L, Illiano E, Salvatore M, Franzese M. New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis. Front Chem 2020;8:600. [PMID: 32850635 DOI: 10.3389/fchem.2020.00600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Spodzieja M, Kuncewicz K, Sieradzan A, Karczyńska A, Iwaszkiewicz J, Cesson V, Węgrzyn K, Zhukov I, Maszota-Zieleniak M, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. Int J Mol Sci 2020;21:E636. [PMID: 31963646 DOI: 10.3390/ijms21020636] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
26 Sové RJ, Jafarnejad M, Zhao C, Wang H, Ma H, Popel AS. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications. CPT Pharmacometrics Syst Pharmacol 2020;9:484-97. [PMID: 32618119 DOI: 10.1002/psp4.12546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
27 Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, Morihiro T, Kubota T, Aoyama K, Kikuchi S, Nishizaki M, Kagawa S, Tazawa H, Mizuguchi H, Urata Y, Fujiwara T. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Mol Ther 2020;28:794-804. [PMID: 31991110 DOI: 10.1016/j.ymthe.2020.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
28 Vara BA, Levi SM, Achab A, Candito DA, Fradera X, Lesburg CA, Kawamura S, Lacey BM, Lim J, Methot JL, Xu Z, Xu H, Smith DM, Piesvaux JA, Miller JR, Bittinger M, Ranganath SH, Bennett DJ, DiMauro EF, Pasternak A. Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds. ACS Med Chem Lett 2021;12:653-61. [PMID: 33859804 DOI: 10.1021/acsmedchemlett.1c00096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Wang DP, Kang K, Lin Q, Hai J. Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta-Analysis. Clin Transl Sci 2020;13:179-88. [PMID: 31550075 DOI: 10.1111/cts.12700] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
30 DePalo DK, Tarhini A, Zager JS. The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. Expert Opin Investig Drugs 2022;:1-10. [PMID: 34996314 DOI: 10.1080/13543784.2022.2027366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Menz BD, Johnson JL, Gillard DF, Chong W, Ward MB. The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events. J Pharm Pract 2021;34:386-96. [PMID: 33969772 DOI: 10.1177/0897190019872937] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Phillips D, Schürch CM, Khodadoust MS, Kim YH, Nolan GP, Jiang S. Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. Front Immunol 2021;12:687673. [PMID: 34093591 DOI: 10.3389/fimmu.2021.687673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Guo T, Wang Z, Liu Y. Establishment and verification of a prognostic tumor microenvironment-based and immune-related gene signature in colon cancer. J Gastrointest Oncol 2021;12:2172-91. [PMID: 34790383 DOI: 10.21037/jgo-21-522] [Reference Citation Analysis]
34 O'Donnell JC, Le TK, Dobrin R, Higashi M, Pereira A, Wagner S, Yang A, Hukkelhoven M. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. Future Oncol 2021;17:333-47. [PMID: 33074018 DOI: 10.2217/fon-2020-0591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wood LS. Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types. J Adv Pract Oncol 2019;10:47-62. [PMID: 33014517 DOI: 10.6004/jadpro.2019.10.2.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
36 Daisy Precilla S, Kuduvalli SS, Thirugnanasambandhar Sivasubramanian A. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond. Cell Biol Int 2021;45:18-53. [PMID: 33049091 DOI: 10.1002/cbin.11484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Saab S, Zalzale H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Front Immunol 2020;11:159. [PMID: 32117295 DOI: 10.3389/fimmu.2020.00159] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
38 Cocco C, Morandi F, Airoldi I. Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells 2021;10:927. [PMID: 33920505 DOI: 10.3390/cells10040927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Kos S, Lopes A, Preat V, Cemazar M, Lampreht Tratar U, Ucakar B, Vanvarenberg K, Sersa G, Vandermeulen G. Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. PLoS One 2019;14:e0217762. [PMID: 31150505 DOI: 10.1371/journal.pone.0217762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
40 Velayutham M, Sarkar P, Rajakrishnan R, Kuppusamy P, Juliet A, Arockiaraj J. Antiproliferation of MP12 derived from a fungus, Aphanomyces invadans virulence factor, cysteine-rich trypsin inhibitor on human laryngeal epithelial cells, and in vivo zebrafish embryo model. Toxicon 2022:S0041-0101(22)00060-5. [PMID: 35217022 DOI: 10.1016/j.toxicon.2022.02.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Rao C, Jin J, Lu J, Wang C, Wu Z, Zhu Z, Tu M, Su Z, Li Q. A Multielement Prognostic Nomogram Based on a Peripheral Blood Test, Conventional MRI and Clinical Factors for Glioblastoma. Front Neurol 2022;13:822735. [DOI: 10.3389/fneur.2022.822735] [Reference Citation Analysis]
42 Tavares MR, Pechar M, Chytil P, Etrych T. Polymer-Based Drug-Free Therapeutics for Anticancer, Anti-Inflammatory, and Antibacterial Treatment. Macromol Biosci 2021;21:e2100135. [PMID: 34008348 DOI: 10.1002/mabi.202100135] [Reference Citation Analysis]
43 Wernitznig D, Kiakos K, Del Favero G, Harrer N, Machat H, Osswald A, Jakupec MA, Wernitznig A, Sommergruber W, Keppler BK. First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. Metallomics 2019;11:1044-8. [DOI: 10.1039/c9mt00051h] [Cited by in Crossref: 47] [Cited by in F6Publishing: 19] [Article Influence: 15.7] [Reference Citation Analysis]
44 D'Arcangelo D, Scatozza F, Giampietri C, Marchetti P, Facchiano F, Facchiano A. Ion Channel Expression in Human Melanoma Samples: In Silico Identification and Experimental Validation of Molecular Targets. Cancers (Basel) 2019;11:E446. [PMID: 30934896 DOI: 10.3390/cancers11040446] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
45 Li Y, Zhao R, Cheng K, Zhang K, Wang Y, Zhang Y, Li Y, Liu G, Xu J, Xu J, Anderson GJ, Shi J, Ren L, Zhao X, Nie G. Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition. ACS Nano 2020. [PMID: 33232124 DOI: 10.1021/acsnano.0c03776] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
46 Zuo S, Song J, Zhang J, He Z, Sun B, Sun J. Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what? Theranostics 2021;11:7471-87. [PMID: 34158861 DOI: 10.7150/thno.59953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
47 Sancho-Araiz A, Mangas-Sanjuan V, Trocóniz IF. The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. Pharmaceutics 2021;13:1016. [PMID: 34371708 DOI: 10.3390/pharmaceutics13071016] [Reference Citation Analysis]
48 Wang S, Xie K, Liu T. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters. Front Immunol 2021;12:690112. [PMID: 34367148 DOI: 10.3389/fimmu.2021.690112] [Reference Citation Analysis]
49 Fang Z, Lin L, Tu Z, Zhu X, Li J, Luo P, Huang K, Wu L. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas. Cancer Med 2022. [PMID: 35702880 DOI: 10.1002/cam4.4945] [Reference Citation Analysis]
50 Martini S, Figini M, Croce A, Frigerio B, Pennati M, Gianni AM, De Marco C, Daidone MG, Argueta C, Landesman Y, Zaffaroni N, Satta A. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. Cells 2020;9:E2231. [PMID: 33023194 DOI: 10.3390/cells9102231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Gevaert T, Van Eycke YR, Vanden Broeck T, Van Poppel H, Salmon I, Rorive S, Muilwijk T, Claessens F, De Ridder D, Joniau S, Decaestecker C. The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. PLoS One 2020;15:e0244663. [PMID: 33370412 DOI: 10.1371/journal.pone.0244663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
52 Solinas C, Aiello M, De Silva P, Gu-trantien C, Migliori E, Willard-gallo K. Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology 2019;142:35-43. [DOI: 10.1016/j.critrevonc.2019.07.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
53 Garrido P, Pujol JL, Kim ES, Lee JM, Tsuboi M, Gómez-Rueda A, Benito A, Moreno N, Gorospe L, Dong T, Blin C, Rodrik-Outmezguine V, Passos VQ, Mok TS. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncol 2021;17:1459-72. [PMID: 33648347 DOI: 10.2217/fon-2020-1098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wimalachandra DC, Li Y, Liu J, Shikha S, Zhang J, Lim Y, Zhang Y. Microfluidic-Based Immunomodulation of Immune Cells Using Upconversion Nanoparticles in Simulated Blood Vessel–Tumor System. ACS Appl Mater Interfaces 2019;11:37513-23. [DOI: 10.1021/acsami.9b15178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
55 Grumberg V, Roze S, Chevalier J, Borrill J, Gaudin AF, Branchoux S. A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. Int J Technol Assess Health Care 2022;38:e28. [PMID: 35331347 DOI: 10.1017/S0266462322000125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Palmisano A, Krushkal J, Li M, Fang J, Sonkin D, Wright G, Yee L, Zhao Y, Mcshane L. Bioinformatics Tools and Resources for Cancer Immunotherapy Study. In: Thurin M, Cesano A, Marincola FM, editors. Biomarkers for Immunotherapy of Cancer. New York: Springer; 2020. pp. 649-78. [DOI: 10.1007/978-1-4939-9773-2_29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Pouliliou S, Nikolaidis C, Drosatos G. Current trends in cancer immunotherapy: a literature-mining analysis. Cancer Immunol Immunother 2020;69:2425-39. [PMID: 32556496 DOI: 10.1007/s00262-020-02630-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Zhao X, Shao C. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade. Cancers (Basel) 2020;12:E2762. [PMID: 32992835 DOI: 10.3390/cancers12102762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
59 Bermudez MV, Papa S. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy. Rheumatology (Oxford) 2019;58:vii1-6. [PMID: 31816083 DOI: 10.1093/rheumatology/kez402] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Caliendo F, Dukhinova M, Siciliano V. Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology. Front Bioeng Biotechnol 2019;7:43. [PMID: 30937303 DOI: 10.3389/fbioe.2019.00043] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
61 Desai K, Hubben A, Ahluwalia M. The Role of Checkpoint Inhibitors in Glioblastoma. Target Oncol 2019;14:375-94. [PMID: 31290002 DOI: 10.1007/s11523-019-00655-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
62 Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol 2020;20:209-15. [DOI: 10.1038/s41577-019-0264-y] [Cited by in Crossref: 104] [Cited by in F6Publishing: 106] [Article Influence: 52.0] [Reference Citation Analysis]
63 Asai N, Kubo A, Suzuki S, Murotani K, Numanami H, Yoshikawa K, Ueda R, Yamaguchi E. CCR4 Expression in Tumor-Infiltrating Regulatory T Cells in Patients with Squamous Cell Carcinoma of the Lung: A Prognostic Factor for Relapse and Survival. Cancer Invest 2019;37:163-73. [PMID: 30907146 DOI: 10.1080/07357907.2019.1582848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tavares MR, Hrabánková K, Konefał R, Kaňa M, Říhová B, Etrych T, Šírová M, Chytil P. HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy. Pharmaceutics 2021;13:179. [PMID: 33525658 DOI: 10.3390/pharmaceutics13020179] [Reference Citation Analysis]
65 Vugmeyster Y, Wilkins J, Koenig A, El Bawab S, Dussault I, Ojalvo LS, De Banerjee S, Klopp-Schulze L, Khandelwal A. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1. Clin Pharmacol Ther 2020;108:566-74. [PMID: 31955412 DOI: 10.1002/cpt.1776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
66 Li X, Zhu S, Yin P, Zhang S, Xu J, Zhang Q, Shi S, Zhang T. Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects. Drug Deliv 2021;28:1849-60. [PMID: 34515617 DOI: 10.1080/10717544.2021.1971797] [Reference Citation Analysis]
67 Kametani Y, Ohno Y, Ohshima S, Tsuda B, Yasuda A, Seki T, Ito R, Tokuda Y. Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors. Int J Mol Sci 2019;20:E6337. [PMID: 31888191 DOI: 10.3390/ijms20246337] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
68 Ascione A, Arenaccio C, Mallano A, Flego M, Gellini M, Andreotti M, Fenwick C, Pantaleo G, Vella S, Federico M. Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. BMC Biotechnol 2019;19:67. [PMID: 31623599 DOI: 10.1186/s12896-019-0559-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
69 Zhang D, Qian C, Wei H, Qian X. Identification of the Prognostic Value of Tumor Microenvironment-Related Genes in Esophageal Squamous Cell Carcinoma. Front Mol Biosci 2020;7:599475. [PMID: 33381521 DOI: 10.3389/fmolb.2020.599475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Vangala V, Nimmu NV, Khalid S, Kuncha M, Sistla R, Banerjee R, Chaudhuri A. Combating Glioblastoma by Codelivering the Small-Molecule Inhibitor of STAT3 and STAT3siRNA with α5β1 Integrin Receptor-Selective Liposomes. Mol Pharm 2020;17:1859-74. [PMID: 32343904 DOI: 10.1021/acs.molpharmaceut.9b01271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Kumar US, Natarajan A, Massoud TF, Paulmurugan R. FN3 linked nanobubbles as a targeted contrast agent for US imaging of cancer-associated human PD-L1. J Control Release 2022:S0168-3659(22)00226-7. [PMID: 35469983 DOI: 10.1016/j.jconrel.2022.04.030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Rocco D, Della Gravara L, Battiloro C, Gridelli C. The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer. Expert Opin Biol Ther 2021;21:303-9. [PMID: 33355496 DOI: 10.1080/14712598.2021.1869209] [Reference Citation Analysis]
73 Tay AHM, Prieto-Díaz R, Neo S, Tong L, Chen X, Carannante V, Önfelt B, Hartman J, Haglund F, Majellaro M, Azuaje J, Garcia-Mera X, Brea JM, Loza MI, Jespers W, Gutierrez-de-Teran H, Sotelo E, Lundqvist A. A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models. J Immunother Cancer 2022;10:e004592. [PMID: 35580926 DOI: 10.1136/jitc-2022-004592] [Reference Citation Analysis]
74 Xu C, Marelli B, Qi J, Qin G, Yu H, Wang H, Jenkins MH, Lo KM, Lan Y. NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models. Transl Oncol 2021;16:101322. [PMID: 34954456 DOI: 10.1016/j.tranon.2021.101322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Hobernik D, Bros M. DNA Vaccines-How Far From Clinical Use? Int J Mol Sci 2018;19:E3605. [PMID: 30445702 DOI: 10.3390/ijms19113605] [Cited by in Crossref: 144] [Cited by in F6Publishing: 132] [Article Influence: 36.0] [Reference Citation Analysis]
76 Karimi S, Mansouri S, Nassiri F, Bunda S, Singh O, Brastianos PK, Dunn IF, Zadeh G. Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status. J Neurooncol 2021;151:443-9. [PMID: 33611710 DOI: 10.1007/s11060-020-03584-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Jiang M, Ren L, Chen Y, Wang H, Wu H, Cheng S, Li G, Yu S. Identification of a Hypoxia-Related Signature for Predicting Prognosis and the Immune Microenvironment in Bladder Cancer. Front Mol Biosci 2021;8:613359. [PMID: 34026819 DOI: 10.3389/fmolb.2021.613359] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Sobhani N, Corona SP, Roviello G, Bagby S, D'Angelo A, Iezzi G, Generali D. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors? Future Oncol 2020;16:1327-30. [PMID: 32396404 DOI: 10.2217/fon-2020-0311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Collery P, Veena V, Harikrishnan A, Desmaele D. The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers. Invest New Drugs 2019;37:973-83. [PMID: 30632005 DOI: 10.1007/s10637-019-00727-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
80 Shirbhate E, Veerasamy R, Boddu SH, Tiwari AK, Rajak H. Histone deacetylase inhibitor-based oncolytic virotherapy: a promising strategy for cancer treatment. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.02.009] [Reference Citation Analysis]
81 El-Kadiry AE, Beaudoin S, Plouffe S, Rafei M. Accum™ Technology: A Novel Conjugable Primer for Onco-Immunotherapy. Molecules 2022;27:3807. [PMID: 35744930 DOI: 10.3390/molecules27123807] [Reference Citation Analysis]
82 Jentzsch V, Davis JAA, Djamgoz MBA. Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management. Cancers (Basel) 2020;12:E3096. [PMID: 33114159 DOI: 10.3390/cancers12113096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
83 Qi Z, Xu Z, Zhang L, Zou Y, Li J, Yan W, Li C, Liu N, Wu H. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nat Commun 2022;13:182. [PMID: 35013322 DOI: 10.1038/s41467-021-27833-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
84 Pirš B, Škof E, Smrkolj V, Smrkolj Š. Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment. Cancers (Basel) 2022;14:631. [PMID: 35158899 DOI: 10.3390/cancers14030631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Basilotta R, Mannino D, Filippone A, Casili G, Prestifilippo A, Colarossi L, Raciti G, Esposito E, Campolo M. Role of Calixarene in Chemotherapy Delivery Strategies. Molecules 2021;26:3963. [PMID: 34209495 DOI: 10.3390/molecules26133963] [Reference Citation Analysis]
86 Wu K, Yi M, Qin S, Chu Q, Zheng X, Wu K. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Exp Hematol Oncol 2019;8:26. [PMID: 31673481 DOI: 10.1186/s40164-019-0150-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
87 Augustin LB, Milbauer L, Hastings SE, Leonard AS, Saltzman DA, Schottel JL. Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer. J Drug Target 2021;29:430-8. [PMID: 33183080 DOI: 10.1080/1061186X.2020.1850739] [Reference Citation Analysis]
88 Kolenda T, Guglas K, Baranowski D, Sobocińska J, Kopczyńska M, Teresiak A, Bliźniak R, Lamperska K. cfRNAs as biomarkers in oncology - still experimental or applied tool for personalized medicine already? Rep Pract Oncol Radiother 2020;25:783-92. [PMID: 32904167 DOI: 10.1016/j.rpor.2020.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
89 van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RS, de Groot DJA, de Vries EG. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics 2020;10:1708-18. [PMID: 32042331 DOI: 10.7150/thno.38339] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
90 Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. Front Immunol 2020;11:2105. [PMID: 33013886 DOI: 10.3389/fimmu.2020.02105] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
91 Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw A, Cheung A, Osborn G, Hoffmann RM, Nakamura M, Laddach R, Geh JLC, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Josephs DH, Papa S, Lacy KE, Karagiannis SN. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. Eur J Immunol 2021;51:544-56. [PMID: 33450785 DOI: 10.1002/eji.202048747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
92 Martin B, Märkl B. Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer. Visc Med 2019;35:3-10. [PMID: 31312644 DOI: 10.1159/000496565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
93 Lee H, Na KJ, Choi H. Differences in Tumor Immune Microenvironment in Metastatic Sites of Breast Cancer. Front Oncol 2021;11:649004. [PMID: 33816302 DOI: 10.3389/fonc.2021.649004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 Davies MJ. PD-1/PD-L1 Inhibitors for Non-Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. J Adv Pract Oncol 2019;10:21-35. [PMID: 33014515 DOI: 10.6004/jadpro.2019.10.2.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
95 Wang S, Wang X, Zhou X, Lyerly HK, Morse MA, Ren J. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin Biol Ther. 2020;20:601-607. [PMID: 32033522 DOI: 10.1080/14712598.2020.1728250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
96 Prasad R, Jain N, Conde J, Srivastava R. Localized nanotheranostics: recent developments in cancer nanomedicine. Materials Today Advances 2020;8:100087. [DOI: 10.1016/j.mtadv.2020.100087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
97 Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, Deshmukh RR. Immunotherapies and Combination Strategies for Immuno-Oncology. Int J Mol Sci 2020;21:E5009. [PMID: 32679922 DOI: 10.3390/ijms21145009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
98 Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. Future Oncol 2021;17:1401-39. [PMID: 33475012 DOI: 10.2217/fon-2020-0967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Lin Y, Pan X, Chen Z, Lin S, Chen S. Identification of an Immune-Related Nine-lncRNA Signature Predictive of Overall Survival in Colon Cancer. Front Genet 2020;11:318. [PMID: 32425969 DOI: 10.3389/fgene.2020.00318] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
100 Lin Z, Chen L, Wu T, Zhang Y, Huang X, Chen Y, Chen J, Xu Y. Prognostic Value of SPOCD1 in Esophageal Squamous Cell Carcinoma: A Comprehensive Study Based on Bioinformatics and Validation. Front Genet 2022;13:872026. [PMID: 35646092 DOI: 10.3389/fgene.2022.872026] [Reference Citation Analysis]
101 Chowdhury P, Dey P, De D, Ghosh U. Gamma ray-induced in vitro cell migration via EGFR/ERK/Akt/p38 activation is prevented by olaparib pretreatment. Int J Radiat Biol 2020;96:651-60. [PMID: 31914341 DOI: 10.1080/09553002.2020.1711461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
102 Zhang X, Zhang Y, Zheng H, He Y, Jia H, Zhang L, Lin C, Chen S, Zheng J, Yang Q, Liu T, Pan X, Zhang H, Wang C, Ren L, Shan W. In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy. Acta Biomater 2021;134:633-48. [PMID: 34329780 DOI: 10.1016/j.actbio.2021.07.055] [Reference Citation Analysis]
103 Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 2021;70:1965-76. [PMID: 33416944 DOI: 10.1007/s00262-020-02820-4] [Reference Citation Analysis]
104 Pan S, Zhao X, Shao C, Fu B, Huang Y, Zhang N, Dou X, Zhang Z, Qiu Y, Wang R, Jin M, Kong D. STIM1 promotes angiogenesis by reducing exosomal miR-145 in breast cancer MDA-MB-231 cells. Cell Death Dis 2021;12:38. [PMID: 33414420 DOI: 10.1038/s41419-020-03304-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
105 Jaffar-aghaei M, Khanipour F, Maghsoudi A, Sarvestani R, Mohammadian M, Maleki M, Havasi F, Rahmani H, Karagah A, Kazemali M. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106171] [Reference Citation Analysis]
106 Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, Mcdonald L, Karagiannis SN, Taams LS, Powell N, Cope A, Papa S. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol 2020;200:141-54. [PMID: 31989585 DOI: 10.1111/cei.13421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
107 Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Mol Biol Rep 2021;48:8075-95. [PMID: 34671902 DOI: 10.1007/s11033-021-06752-9] [Reference Citation Analysis]
108 Jiao R, Allen KJH, Malo ME, Rickles D, Dadachova E. Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model. Int J Mol Sci 2020;21:E773. [PMID: 31991626 DOI: 10.3390/ijms21030773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
109 Li Z, Sun Y, Lai M, Zhou Y, Qiu M. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. International Immunopharmacology 2022;109:108790. [DOI: 10.1016/j.intimp.2022.108790] [Reference Citation Analysis]
110 Gravara LD, Battiloro C, Cantile R, Letizia A, Vitiello F, Montesarchio V, Rocco D. Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? Lung Cancer Manag 2020;9:LMT22. [PMID: 32256708 DOI: 10.2217/lmt-2019-0018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
111 Mikaelian AG, Traboulay E, Zhang XM, Yeritsyan E, Pedersen PL, Ko YH, Matalka KZ. Pleiotropic Anticancer Properties of Scorpion Venom Peptides: Rhopalurus princeps Venom as an Anticancer Agent. Drug Des Devel Ther 2020;14:881-93. [PMID: 32161447 DOI: 10.2147/DDDT.S231008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
112 Raj AT, Kheur S, Gupta AA, Patil VR, Kharat A. The need for combination immunotherapy in oncology. Oral Oncol 2019;91:123-4. [PMID: 30786965 DOI: 10.1016/j.oraloncology.2019.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Malyszko J, Lee MW, Capasso G, Kulicki P, Matuszkiewicz-rowinska J, Ronco P, Stevens P, Tesarova P, Viggiano D, Capasso A. How to assess kidney function in oncology patients. Kidney International 2020;97:894-903. [DOI: 10.1016/j.kint.2019.12.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Huang F, Zhao J, Wei Y, Wen Z, Zhang Y, Wang X, Shen Y, Wang LX, Pan N. Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells. Int J Nanomedicine 2020;15:1021-35. [PMID: 32103954 DOI: 10.2147/IJN.S237578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
115 Xu Q, Rangaswamy US, Wang W, Robbins SH, Harper J, Jin H, Cheng X. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. Int J Cancer 2020;146:531-41. [PMID: 31584185 DOI: 10.1002/ijc.32694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
116 Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, Wang X, Peng C, Zhou C, Zhou L, Li X, Shi H, Wu W, Long X, Wu C, Liao W. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun 2019;10:5421. [PMID: 31780645 DOI: 10.1038/s41467-019-13204-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
117 Cella F, Siciliano V. Protein-based parts and devices that respond to intracellular and extracellular signals in mammalian cells. Curr Opin Chem Biol 2019;52:47-53. [PMID: 31158655 DOI: 10.1016/j.cbpa.2019.04.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
118 Hutchings C, Phillips JA, Djamgoz MBA. Nerve input to tumours: Pathophysiological consequences of a dynamic relationship. Biochim Biophys Acta Rev Cancer 2020;1874:188411. [PMID: 32828885 DOI: 10.1016/j.bbcan.2020.188411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
119 Zhang Z, Wu Y, Yu C, Li Z, Xu L. Comprehensive analysis of immune related lncRNAs in the tumor microenvironment of stage II-III colorectal cancer. J Gastrointest Oncol 2021;12:2232-43. [PMID: 34790388 DOI: 10.21037/jgo-21-594] [Reference Citation Analysis]
120 Small S, Numan Y, Platanias LC. Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies. Biomedicines 2021;9:1631. [PMID: 34829860 DOI: 10.3390/biomedicines9111631] [Reference Citation Analysis]
121 Aramini B, Masciale V, Grisendi G, Banchelli F, D'Amico R, Maiorana A, Morandi U, Dominici M, Haider KH. Cancer stem cells and macrophages: molecular connections and future perspectives against cancer. Oncotarget 2021;12:230-50. [PMID: 33613850 DOI: 10.18632/oncotarget.27870] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
122 Zhao X, Chen J, Qiu M, Li Y, Glass Z, Xu Q. Imidazole‐Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes. Angew Chem Int Ed 2020;59:20083-9. [DOI: 10.1002/anie.202008082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
123 Antonarelli G, Corti C, Tarantino P, Ascione L, Cortes J, Romero P, Mittendorf EA, Disis ML, Curigliano G. Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Ann Oncol 2021:S0923-7534(21)04457-4. [PMID: 34500046 DOI: 10.1016/j.annonc.2021.08.2153] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Hoffmann PR, Hoffmann FW, Premeaux TA, Fujita T, Soprana E, Panigada M, Chew GM, Richard G, Hindocha P, Menor M, Khadka VS, Deng Y, Moise L, Ndhlovu LC, Siccardi A, Weinberg AD, De Groot AS, Bertino P. Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models. Front Oncol 2019;9:720. [PMID: 31428586 DOI: 10.3389/fonc.2019.00720] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
125 Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. J Immunother Cancer 2020;8:e000493. [PMID: 32303618 DOI: 10.1136/jitc-2019-000493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
126 Cheng HW, Tsao HY, Chiang CS, Chen SY. Advances in Magnetic Nanoparticle-Mediated Cancer Immune-Theranostics. Adv Healthc Mater 2021;10:e2001451. [PMID: 33135398 DOI: 10.1002/adhm.202001451] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
127 Rafei-Shamsabadi D, Lehr S, von Bubnoff D, Meiss F. Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. Cancer Immunol Immunother 2019;68:1417-28. [PMID: 31422446 DOI: 10.1007/s00262-019-02377-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
128 Zokaei E, Darbeheshti F, Rezaei N. Prospect of exosomal circular RNAs in breast Cancer: presents and future. Mol Biol Rep 2022. [PMID: 35534582 DOI: 10.1007/s11033-022-07472-4] [Reference Citation Analysis]
129 Hemming ML, Nathenson MJ, Lin JR, Mei S, Du Z, Malik K, Marino-Enriquez A, Jagannathan JP, Sorger PK, Bertagnolli M, Sicinska E, Demetri GD, Santagata S. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol 2020;4:79-90. [PMID: 32133433 DOI: 10.1200/po.19.00287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
130 Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet 2019;58:835-57. [PMID: 30815848 DOI: 10.1007/s40262-019-00748-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 38.5] [Reference Citation Analysis]
131 Steinel NC, Lee EM, Viggiano D, Capasso A, Lee MW. The renal adverse effects of cancer immunotherapy. J Nephrol 2020;33:467-81. [PMID: 31912436 DOI: 10.1007/s40620-019-00691-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
132 Canese R, Bazzocchi A, Blandino G, Carpinelli G, De Nuccio C, Gion M, Moretti F, Soricelli A, Spessotto P, Iorio E. The role of molecular and imaging biomarkers in the evaluation of inflammation in oncology. Int J Biol Markers 2020;35:5-7. [PMID: 32079466 DOI: 10.1177/1724600819897926] [Reference Citation Analysis]
133 Shi X, Sun J, Li H, Lin H, Xie W, Li J, Tan W. Antitumor efficacy of interferon‐γ‐modified exosomal vaccine in prostate cancer. Prostate 2020;80:811-23. [DOI: 10.1002/pros.23996] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
134 Conciatori F, Bazzichetto C, Falcone I, Ciuffreda L, Ferretti G, Vari S, Ferraresi V, Cognetti F, Milella M. PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. Int J Mol Sci 2020;21:E5337. [PMID: 32727102 DOI: 10.3390/ijms21155337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
135 Harui A, McLachlan SM, Rapoport B, Zarembinski TI, Roth MD. Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity. Cancer Immunol Immunother 2020;69:1737-49. [PMID: 32333082 DOI: 10.1007/s00262-020-02579-8] [Reference Citation Analysis]
136 Vallejo Ardila DL, Walsh KA, Fifis T, Paolini R, Kastrappis G, Christophi C, Perini MV. Immunomodulatory effects of renin-angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases. J Immunother Cancer 2020;8:e000487. [PMID: 32448803 DOI: 10.1136/jitc-2019-000487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
137 Meng Y, Sun J, Qu N, Zhang G, Yu T, Piao H. Application of Radiomics for Personalized Treatment of Cancer Patients. Cancer Manag Res 2019;11:10851-8. [PMID: 31920394 DOI: 10.2147/CMAR.S232473] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
138 McKeon A, Zekeridou A. Autoimmune encephalitis management: MS centers and beyond. Mult Scler 2020;26:1618-26. [PMID: 32052703 DOI: 10.1177/1352458520905485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Malonis RJ, Lai JR, Vergnolle O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem Rev 2020;120:3210-29. [PMID: 31804810 DOI: 10.1021/acs.chemrev.9b00472] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 28.0] [Reference Citation Analysis]
140 Künkele KP, Wesch D, Oberg HH, Aichinger M, Supper V, Baumann C. Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy? Cells 2020;9:E829. [PMID: 32235616 DOI: 10.3390/cells9040829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
141 Voeller J, Erbe AK, Slowinski J, Rasmussen K, Carlson PM, Hoefges A, VandenHeuvel S, Stuckwisch A, Wang X, Gillies SD, Patel RB, Farrel A, Rokita JL, Maris J, Hank JA, Morris ZS, Rakhmilevich AL, Sondel PM. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. J Immunother Cancer 2019;7:344. [PMID: 31810498 DOI: 10.1186/s40425-019-0823-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
142 Gupta A, Arora P, Brenner D, Vanderpuye-Orgle J, Boyne DJ, Edmondson-Jones M, Parkhomenko E, Stevens W, Dudani S, Heng DYC, Wagner S, Borrill J, Wu E. Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clin Cancer Inform 2021;5:326-37. [PMID: 33764818 DOI: 10.1200/CCI.20.00107] [Reference Citation Analysis]
143 Huang P, Xu L, Jin M, Li L, Ke Y, Zhang M, Zhang K, Lu K, Huang G. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients. Genes 2022;13:951. [DOI: 10.3390/genes13060951] [Reference Citation Analysis]
144 Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer 2022;10:e004223. [PMID: 35288468 DOI: 10.1136/jitc-2021-004223] [Reference Citation Analysis]
145 Agur Z, Elishmereni M, Foryś U, Kogan Y. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models. Clin Pharmacol Ther 2020;108:515-27. [PMID: 32535891 DOI: 10.1002/cpt.1942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
146 Esteban-Rodríguez I, Ruiz Bravo-Burguillos E, Rosas R, Losantos I, Rodríguez-Antolín C, de Castro J. [Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data]. Rev Esp Patol 2020;53:10-8. [PMID: 31932004 DOI: 10.1016/j.patol.2019.04.003] [Reference Citation Analysis]
147 Liu Y, Guo X, Zhan L, Wang L, Wang X, Jiang M. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients. Comput Math Methods Med 2021;2021:4468140. [PMID: 34422089 DOI: 10.1155/2021/4468140] [Reference Citation Analysis]
148 Seliger B. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Front Immunol 2019;10:999. [PMID: 31178856 DOI: 10.3389/fimmu.2019.00999] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]